GEN inCode is a genetic testing business specialising in the risk assessment and prediction of cardiovascular disease.
Gen inCode has raised €3.8M across 1 funding round from 1 investor, most recently a Growth/Late round in Aug 2020. Based in Manchester, UK; founded 2018; active in Healthtech. Data as of 7 Aug 2026.
Timing: dormant vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2020-08-27 | Growth/Late |
| €3.8M |
| Maven Capital Partners |
| View deal → |
